Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Nordea Equities Healthcare Seminar 2025
9 slides from Vitrolife Ab's conference presentation, May 8, 2025
Slide 1: Vitrolife AB (publ) - Nordea Equities Healthcare Seminar 2025
Vitrolife AB (publ) Nordea Equities Healthcare Seminar 2025 2025-05-08 Bronwyn Brophy O'Connor, CEO Helena Wennerström, Acting CFO
Slide 2: The sheer magnitude of the global infertility healthcare issue
The sheer magnitude of the global infertility healthcare issue Adults >20 years old Adults >20 living Adults affected Coronary artery disease with Diabetes by infertility 2 Source: CDC International Diabetes Foundation, ESHRE, SART
Slide 3: Significant market opportunity in reproductive health
Significant market opportunity in reproductive health Successful treatment outcomes ~33% *** 1 in 6 134 M Access and affordability constraining ~5% people globally is babies born annually** estimated cycle growth affected by infertility* < 1% via IVF growth in coming years *Source: World Health Organ
Slide 4: 5 Strategic Pillars focusing on Innovation, Growth and Operational Excellence
5 Strategic Pillars focusing on Innovation, Growth and Operational Excellence INNOVATION GROWTH OPERATIONS 1 2 3 4 5 Own the platform Innovate to Accelerate Optimise go-to- Drive operational connecting expand growth in key market model excellence products and leadership markets services • Drive embr
Slide 5: Revenue per segment and product group Q1 2025
Revenue per segment and product group Q1 2025 Consumables APAC 41% 28% Americas 32% Genetics 41% Revenue by Revenue by geography product groups EMEA Technologies 40% 18% Good geographic balance has proved critical in Well balanced from a product group perspective. the changing macroeconomic enviro
Slide 6: Focus for 2025
Focus for 2025 1. Continue to drive share gain in key markets leveraging the full breadth of the portfolio. 2. Accelerate penetration of our combined EmbryoScope and lab control solutions. Growth 3. Deliver best in class quality and customer service to further differentiate from competitors. 1. Prio
Slide 7: Tariff update as per May 6th
Tariff update as per May 6th Current status: • US: Imposed 145% tariffs on Chinese and 20% on EU (currently a 90 days pause -10% applies) medical devices to promote domestic manufacturing. • EU: Planning retaliatory tariffs up to 25% on U.S. goods, possibly including medical devices, unless a trade
Slide 8: Reasons to invest in Vitrolife AB (publ)
Reasons to invest in Vitrolife AB (publ) • Underlying resilient market growth. • High quality brands linked with outstanding service and support. • Proven track record of profitable growth. • Innovation and technology leader within fertility. • Ambitious strategy and long-term objectives. Contact: in
Slide 9: Disclaimer
Disclaimer This presentation may contain estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there